Assenagon Asset Management S.A. Biocryst Pharmaceuticals Inc Transaction History

Assenagon Asset Management S.A.

$65.1 Billion
Q3 2025

A detailed history of Assenagon Asset Management S.A. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 3,092,592 shares of BCRX stock, worth $22.4 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

3,092,592

Previous 3,620,637 14.58%

Holding current value

$22.4 Million

Previous $32.4 Million 27.64%

% of portfolio

0.04%

Previous 0.05%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Oct 07, 2025	SELL	$7.55 - $9.06 $3.99 Million - $4.78 Million	-528,045 Reduced 14.58%	3,092,592 $23.5 Million
Q2 2025 Jul 11, 2025	BUY	$6.41 - $11.19 $23.1 Million - $40.4 Million	3,606,566 Added 25631.2%	3,620,637 $32.4 Million
Q3 2024 Oct 23, 2024	SELL	$6.41 - $8.69 $325,858 - $441,764	-50,836 Reduced 78.32%	14,071 $106,000
Q2 2024 Jul 18, 2024	SELL	$4.13 - $6.79 $1.33 Million - $2.19 Million	-321,978 Reduced 83.22%	64,907 $401,000
Q1 2024 Apr 24, 2024	SELL	$4.89 - $7.65 $696,991 - $1.09 Million	-142,534 Reduced 26.92%	386,885 $1.97 Million
Q4 2023 Jan 17, 2024	SELL	$4.98 - $6.77 $2.89 Million - $3.93 Million	-580,485 Reduced 52.3%	529,419 $3.17 Million
Q3 2023 Nov 06, 2023	SELL	$6.71 - $7.92 $28.3 Million - $33.4 Million	-4,223,010 Reduced 79.19%	1,109,904 $7.86 Million
Q2 2023 Jul 25, 2023	BUY	$6.96 - $8.81 $2.54 Million - $3.22 Million	365,077 Added 7.35%	5,332,914 $37.5 Million
Q1 2023 Apr 18, 2023	BUY	$7.94 - $11.84 $18.9 Million - $28.1 Million	2,377,445 Added 91.78%	4,967,837 $41.4 Million
Q4 2022 Jan 12, 2023	SELL	$10.5 - $14.2 $270,532 - $365,863	-25,765 Reduced 0.98%	2,590,392 $29.7 Million
Q3 2022 Oct 27, 2022	SELL	$10.79 - $14.81 $6.06 Million - $8.32 Million	-561,714 Reduced 17.68%	2,616,157 $33 Million
Q2 2022 Jul 27, 2022	BUY	$7.89 - $17.88 $24.5 Million - $55.6 Million	3,107,027 Added 4385.73%	3,177,871 $33.6 Million
Q1 2022 Apr 25, 2022	BUY	$11.56 - $19.76 $665,948 - $1.14 Million	57,608 Added 435.24%	70,844 $1.15 Million
Q4 2021 Feb 01, 2022	SELL	$11.18 - $15.46 $602,501 - $833,154	-53,891 Reduced 80.28%	13,236 $183,000
Q3 2021 Oct 19, 2021	SELL	$14.21 - $17.65 $9.78 Million - $12.1 Million	-687,905 Reduced 91.11%	67,127 $965,000
Q2 2021 Jul 15, 2021	BUY	$9.5 - $17.24 $6.75 Million - $12.3 Million	710,563 Added 1597.88%	755,032 $11.9 Million
Q1 2021 Apr 26, 2021	BUY	$7.37 - $13.61 $327,736 - $605,223	44,469 New	44,469 $452,000
Q3 2020 Oct 07, 2020	SELL	$3.43 - $5.53 $1.04 Million - $1.68 Million	-303,400 Closed	0 $0
Q2 2020 Jul 21, 2020	BUY	$1.9 - $5.61 $576,460 - $1.7 Million	303,400 New	303,400 $1.45 Million
Q1 2020 Apr 17, 2020	SELL	$1.6 - $4.11 $119,590 - $307,197	-74,744 Closed	0 $0
Q4 2019 Jan 17, 2020	BUY	$1.59 - $3.45 $118,842 - $257,866	74,744 New	74,744 $258,000

Others Institutions Holding BCRX

# of Institutions

314

Shares Held

201M

Call Options Held

930K

Put Options Held

553K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.35B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Biocryst Pharmaceuticals Inc Transaction History